Top

Published in:

01-05-2009 | Personal View

Bone turnover markers: a key tool for understanding osteoporosis

Authors: R. Eastell, P. R. Ebeling

Published in: Osteoporosis International | Special Issue 3/2009

Excerpt

A search of the Web of Science database (http://apps.isiknowledge.com) for publications by Pierre Delmas indicates that he has 30 original publications concerning bone turnover markers out of the 67 publications with citation counts over 100. It is clear that his contribution to the field of bone turnover markers is great and bone turnover marker research has been a large fraction of his contribution to research into metabolic bone diseases. …

Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11(3):337–349PubMedCrossRef

Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11(10):1531–1538PubMed

Garnero P, Shih WJ, Gineyts E, Kalpf D, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700CrossRefPubMed

Sarkar S, Reginster JY, Crans GG, ez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19(3):394–401CrossRefPubMed

Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18(6):1051–1056CrossRefPubMed

Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19(8):1250–1258CrossRefPubMed

Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92(4):1296–1304CrossRefPubMed

Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11[Suppl 6]:S2CrossRefPubMed

Title: Bone turnover markers: a key tool for understanding osteoporosis
Authors: R. Eastell
P. R. Ebeling
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue Special Issue 3/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0695-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bone turnover markers: a key tool for understanding osteoporosis

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2009

Festschrift to honor Professor Pierre D. Delmas

Pharmacologic treatment to prevent fractures: from markers to patients

The International Osteoporosis Foundation: history, objectives and achievements

Bone histomorphometry and bone quality

How basic science informed the Delmas clinical approach

Glucocorticoid-induced osteoporosis